The market is suffering from a 'three-body problem,' says BTIG's Jonathan Krinsky
Jonathan Krinsky, chief market technician at BTIG, joins CNBC's 'The Exchange to discuss his outlook on stocks for 2025, what ...
MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG
BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the shares. The firm ...
24/7 Wall St. on MSN2d
Large-Cap Value Stocks Could Rule in 2025: 4 High-Yield Dividend Winners
Here are four large-cap value stocks that growth and income investors may want to consider now. History suggests they will ...
bovnews2d
BTIG Research Just Downgraded Fiverr International Ltd (FVRR) Stock—What Does This Mean for Investors?
BTIG Research has recently reduced Fiverr International Ltd (FVRR) stock to Neutral rating, as announced on November 4, 2024, according to Finviz. Earlier, on July 2, 2024, UBS had reduced the stock ...
Denali Therapeutics price target lowered to $32 from $35 at BTIG
BTIG analyst Thomas Shrader lowered the firm’s price target on Denali Therapeutics (DNLI) to $32 from $35 and keeps a Buy rating on the shares after the company announced topline data from the Phase 2 ...
Stock rally faces resistance: BTIG's Krinsky
The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...
bovnews5h
Outset Medical Inc (OM) Stock Price Reaches $0.98: What Factors Are Influencing This Level?
On Wednesday, Outset Medical Inc (OM) stock saw a decline, ending the day at $0.98 which represents a decrease of $-0.12 or -10.91% from the prior close of $1.1. The stock opened at $1.15 and touched ...
Here are some of BTIG's top picks for the first half of 2025
BTIG's Krinsky noted that while equity markets in the first half of 2024 were fueled mostly by the surge in mega-cap names ...
Boston Scientific price target raised to $101 from $97 at BTIG
BTIG analyst Marie Thibault raised the firm’s price target on Boston Scientific (BSX) to $101 from $97 and keeps a Buy rating ...
GeneDx management to meet with BTIG
BTIG Life Sciences and Diagnostic Tools Analyst Massaro holds group dinner meeting with CEO Stueland and CFO Feeley on January 13 at 10:30 am.
Investing10d
BTIG sees a risk for 'a bigger January decline' in S&P 500
According to a BTIG strategist, the rally in the index was rejected from the previous support trendline and even though there are still four days left for the Santa Claus rally to deliver gains, there ...